SatRX, a ChemRar group company, is developing PF-00734200 for type 2 diabetes (T2D), one of the most burdensome chronic non-communicable diseases, which is fast reaching epidemic proportions throughout the world. Under the terms of the license,
More information here
Related posts:
- Pfizer Grants ChemRar Group Exclusive License To DPP IVi Type 2 Diabetes Candidate MOSCOW–(Marketwire – Jul 5, 2012) – ChemRar Hi-Tech Centre, the...
- ACT Obtains Exclusive License For Hemangioblast Technology In North America "The market opportunities around diabetes-related diseases alone are vast. Diabetes...
- Medistem Signs Exclusive Worldwide License With Yale University For Treatment Of Type 1 Diabetes Using Stem Cells SAN DIEGO, CA– – Medistem Inc. and Yale University have...
- Medistem Signs Exclusive Worldwide License With Yale University For Treatment "Type 1 diabetes is a rapidly growing poorly-served market. There...
- Islet Sciences Announces Exclusive License Agreement With Yale University To Diminished beta/islet cell function which can be caused by numerous...